|
1）Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355: 1018-28
|
|
|
|
2）Ochs HD, Ziegler SF, Torgerson TR. FOXP3 acts as a rheostat of the immune response. Immunol Rev. 2005; 203: 156-64
|
|
|
|
|
|
3）Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299: 1057-61
|
|
|
|
|
|
4）Smyk-Pearson SK, Bakke AC, Held PK, et al. Rescue of the autoimmune scurfy mouse by partial bone marrow transplantation or by injection with T-enriched splenocytes. Clin Exp immunol. 2003; 133: 193-9
|
|
|
|
|
|
5）Graca L, Thompson S, Lin CY, et al. Both CD4(+)CD25(+)and CD4(+)CD25(-)regulatory cells mediate dominant transplantation tolerance. J Immunol. 2002; 168: 5558-65
|
|
|
|
|
|
6）Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1998; 10: 1969-80
|
|
|
|
|
|
7）Dengler TJ, Szabo G, Sido B, et al. Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation. Transplantation. 1999; 67: 392-8
|
|
|
|
|
|
8）Beyersdorf N, Gaupp S, Balbach K, et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med. 2005; 202: 445-55
|
|
|
|
|
|
9）Evans EJ, Esnouf RM, Manso-Sancho R, et al. Crystal structure of a soluble CD28-Fab complex. Nat Immunol. 2005; 6: 271-9
|
|
|
|
|
|
10）Luhder F, Huang Y, Dennehy KM, et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med. 2003; 197: 955-66
|
|
|
|
|
|
11）Azuma H, Isaka Y, Li X, et al. Superagonistic CD28 antibody induces donor-specific tolerance in rat renal allografts. Am J Transplant. 2008; 8: 2004-14
|
|
|
|
|
|
12）Tipping PG, Holdsworth SR. T cells in crescentic glomerulonephritis. J Am Soc Nephrol. 2006; 17: 1253-63
|
|
|
|
|
|
13）Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8-27
|
|
|
|
|
|
14）Takabatake Y, Li XK, Mizui M, et al. A superagonistic monoclonal antibody for CD28 ameliorates crescentic glomerulonephritis in Wistar-Kyoto rats. Mol Med. 2011; 17: 686-96
|
|
|
|
|
|
15）Miyasato K, Takabatake Y, Kaimori J, et al. CD28 superagonist-induced regulatory T cell expansion ameliorates mesangioproliferative glomerulonephritis in rats. Clin Exp Nephrol. 2011; 15: 50-7
|
|
|
|
|
16）Gogishvili T, Langenhorst D, Luhder F, et al. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PloS One. 2009; 4: e4643
|
|
|
|
|
|
17）Stebbings R, Findlay L, Edwards C, et al. “Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol. 2007; 179: 3325-31
|
|
|
|
|
|
18）Eastwood D, Findlay L, Poole S, et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol. 2010; 161: 512-26
|
|
|
|
|